Immunotherapy is the future of cancer treatment.
We develop these new immunotherapy treatments with the help of generous donors, patients on our trials, and researchers and clinicians across the University, UK and the world.
The new cancer treatments we are developing
Our scientists are:
- engineering new antibody drugs that help our immune system destroy or prevent the growth of cancer cells
- researching new treatments such as checkpoint inhibitor drugs which cause the body's T cells to find and kill cancer cells
- pioneering new approaches to stimulate different immune cells to improve cancer treatments
Clinical trials we are running
Our Southampton Clinical Trials Unit is evaluating the effectiveness of treatments such as:
- an immunotherapy treatment (durvalumab) in boosting the immune systems of people with bladder cancer after radiotherapy treatment
- a checkpoint inhibitor drug (pembrolizumab) in helping to treat diffuse large B cell lymphoma
- a vaccine for HPV-positive (human papilloma virus) people with cancer, called RNA
Patients, find out how to take part in a trial.
Our work across the University
The Centre for Cancer Immunology works with scientists, mathematicians, data experts and engineers from across the University to develop better treatments for cancer.
Collaborators are based both within the Faculty of Medicine at the Southampton General Hopsital site and in other Highfield campus faculties — some at the Institute of Life Sciences.
To work with us to tackle cancer, check our current job opportunities (searching for Centre for Cancer Immunology).